Guidelines for how many times a day you should take Midostaurin and the intervals between doses

Midostaurin is a multi-target kinase inhibitor mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML) and systemic mastocytosis (SM). The drug blocks abnormal signal transduction by inhibiting the activity of multiple kinases such as FLT3, KIT, and PDGFR, thereby inhibiting the growth and differentiation of tumor cells. In order to ensure that the drug maintains effective blood concentration and reduces adverse reactions, the correct frequency and interval of taking the drug are crucial. Clinical studies and official instructions clearly point out that the frequency and interval of midostaurin administration must be strictly followed as prescribed by the doctor and cannot be adjusted at will.

In the treatment of acute myeloid leukemia, the recommended dose of midostaurin is 50 mg twice daily, approximately 12 hours apart. It is usually used in combination with chemotherapy drugs (such as cytarabine and daunorubicin) and is taken daily for 14 days during the induction and consolidation phases of treatment. If the patient is in the maintenance treatment stage, the treatment cycle may be adjusted based on the doctor's judgment. For patients with systemic mastocytosis, the recommended dose is also 50 mg twice daily, taken continuously and not combined with other chemotherapy drugs. It is recommended to take the medication with food to reduce gastrointestinal adverse reactions such as nausea or vomiting.

To ensure stable drug efficacy, patients should try to take the drug at the same time every day, with an interval of about 12 hours. If you accidentally miss a dose and it is more than 6 hours before the next dose, you can take it immediately; if it is close to the time of the next dose, skip the missed dose and do not take two doses at once. During long-term use of midostaurin, doctors usually monitor blood drug concentration, blood cell counts and liver function indicators to prevent drug accumulation or toxic reactions. If serious adverse reactions occur, such as a significant decrease in neutrophils or an increase in liver enzymes, the doctor may temporarily interrupt the medication and adjust the dose.

It should be noted that midostaurin is metabolized mainly through the CYP3A4 enzyme pathway. Therefore, you should avoid using strong CYP3A4 inhibitors or inducers (such as ketoconazole, rifampicin, grapefruit juice, etc.) during medication to avoid affecting the blood concentration of the drug. Patients should also maintain a regular diet and good rest, and avoid taking medication on an empty stomach or with high-fat food. In general, midostaurin's dosing regimen of twice a day with an interval of 12 hours has been clinically proven to be the most reasonable and safe dosing method. Strict compliance with medication timing and monitoring recommendations is key to ensuring stable efficacy and reducing the risk of toxicity.

Reference materials:https://www.drugs.com/